About Makena Auto-Injector

Same Makena. Personalized Patient Support. Innovative Delivery Device.

makena auto injector device
Not actual size

The Makena you know — ready to go

Designed for ease of use, the FDA‑approved Makena subcutaneous auto‑injector is:

efficient box
  • Pre‑filled auto-injector that is ready to use out of the box
  • Administered in ~15 seconds
discreet box
  • Shorter, thinner, nonvisible needle
  • Administered in the back of the upper arm—no need for patients to disrobe
admin box
  • Protective needle guard to help minimize accidental needle‑sticks
  • Appointment flexibility—no need for private exam rooms
Auto-Injector Intramuscular
Why Makena Auto-Injector?1
Auto-Injector Intramuscular
Active ingredient Hydroxyprogesterone caproate Hydroxyprogesterone caproate
Concentration 250 mg/mL 250 mg/mL
Dose 275 mg (1.1 mL) 250 mg (1 mL)
Delivery Single-use, pre-filled disposable auto-injector Traditional needle and syringe
Administration Subcutaneous (SQ) via healthcare provider Intramuscular (IM) via healthcare provider
Injection location

Subcutaneous auto-injector icon

Back of upper arm

Intramuscular injection option for Makena

Upper-outer quadrant of the gluteus maximus
Injection duration ~15 seconds One minute or longer
Needle size Fine 27-gauge, 0.5″ SQ needle 21-gauge, 1.5″ IM needle
Administration Friendly No need for private exam room or for patient to disrobe Below the waist injection

Establishing best practices

Proper injection technique for Makena subcutaneous auto-injector.
Makena Auto-Injector is HCP administered. This easy-to-follow instructional video reviews the proper technique for administering Makena for subcutaneous use. Please see Instructions for Use before administering Makena using the subcutaneous auto‑injector.

Watch video Download

Makena Auto-Injector offers support via Makena Care Connection®. Help ensure your patients receive Makena plus personalized support with these three steps:

icon
COMPLETE the DAW Line

per state laws on the Makena Prescription Form and submit to Makena Care Connection

icon
DISCUSS

the importance of drug + support provided only by Makena with your patients

icon
STAND FIRM

in your prescribing decision to help ensure patients receive Makena + support when pharmacists ask about generic substitution

makena care connection logo

Personalized Patient Support. Healthcare Professional Resources.
More Than Makena. Learn More

You are now leaving makenahcp.com. AMAG Pharmaceuticals is not responsible for the information contained in any of the linked third-party sites. Please review the site's Privacy Policy and Terms of Use, as AMAG's policies do not apply to third-party sites.

Cancel Continue

You are now leaving makenahcp.com. AMAG Pharmaceuticals is not responsible for the information contained in any of the linked third-party sites. Please review the site's Privacy Policy and Terms of Use, as AMAG's policies do not apply to third-party sites.

Cancel Continue

On April 6, 2023, the U.S. Food and Drug Administration (FDA) issued a final decision ordering the withdrawal of the approval of Makena®. FDA has stated that it recognizes that a limited supply of these drugs has already been distributed, including to physicians’ offices and pharmacies. FDA acknowledges that some health care providers might continue to prescribe or administer that limited remaining supply to their patients. However, we recommend health care practitioners consider FDA’s conclusions.

If you have questions about Makena, please call our Medical Information Call Center at +1-877-411-2510, Monday-Friday from 9:00 AM-7:00 PM EST.

Please see Full Prescribing Information for Makena.

This page will redirect to CovisPharma.com in 30 seconds.

PP-MKN-US-00713 08/23